{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T08:53:35Z","timestamp":1781859215325,"version":"3.54.5"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003977","name":"Israel Science Foundation","doi-asserted-by":"publisher","award":["3485\/19"],"award-info":[{"award-number":["3485\/19"]}],"id":[{"id":"10.13039\/501100003977","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.ajo.2025.12.035","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T16:07:07Z","timestamp":1767802027000},"page":"153-160","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Reduced Risk of Non-Neovascular AMD in Cancer Patients Treated With Immune Checkpoint Inhibitors: A Propensity-Matched Cohort Study"],"prefix":"10.1016","volume":"284","author":[{"given":"Natan","family":"Lishinsky-Fischer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1909-6224","authenticated-orcid":false,"given":"Sima","family":"Gharra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itay","family":"Nitzan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itay","family":"Chowers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0043-4354","authenticated-orcid":false,"given":"Jaime","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajo.2025.12.035_bib0001","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/phar.1264","article-title":"Age-related macular degeneration","volume":"33","author":"Cheung","year":"2013","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ajo.2025.12.035_bib0002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms22031170","article-title":"Neovascular macular degeneration: a review of etiology, risk factors, and recent advances in research and therapy","volume":"22","author":"Pugazhendhi","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ajo.2025.12.035_bib0003","first-page":"1","article-title":"The role of the adaptive immune system and T cell dysfunction in neurodegenerative diseases","volume":"19","author":"DeMaio","year":"2022","journal-title":"J Neuroinflam 2022 19:1"},{"key":"10.1016\/j.ajo.2025.12.035_bib0004","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S1350-9462(00)00025-2","article-title":"Immunological and aetiological aspects of macular degeneration","volume":"20","author":"Penfold","year":"2001","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.ajo.2025.12.035_bib0005","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.4049\/jimmunol.2000574","article-title":"Regulatory T cells in angiogenesis","volume":"205","author":"Lu\u017enik","year":"2020","journal-title":"J Immunol"},{"key":"10.1016\/j.ajo.2025.12.035_bib0006","doi-asserted-by":"crossref","first-page":"e860","DOI":"10.1111\/aos.14969","article-title":"Neovascular age-related macular degeneration inactivated during systemic administration of an immune checkpoint inhibitor pembrolizumab for lung cancer","volume":"100","author":"Wakabayashi","year":"2022","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.ajo.2025.12.035_bib0007","doi-asserted-by":"crossref","first-page":"127","DOI":"10.4103\/apjon.apjon_4_17","article-title":"Immune checkpoint inhibitors: an innovation in immunotherapy for the treatment and management of patients with cancer","volume":"4","author":"Dine","year":"2017","journal-title":"Asia Pac J Oncol Nurs"},{"key":"10.1016\/j.ajo.2025.12.035_bib0008","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ajo.2025.12.035_bib0009","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1001\/jama.2023.26074","article-title":"Age-related macular degeneration: a review","volume":"331","author":"Fleckenstein","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.ajo.2025.12.035_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2025.110304","article-title":"Dissecting the biological complexity of age-related macular degeneration: is it one disease, multiple separate diseases, or a spectrum?","volume":"254","author":"Miller","year":"2025","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.ajo.2025.12.035_bib0011","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1038\/s41590-020-0801-7","article-title":"PD-1+ treg cells: a foe in cancer immunotherapy?","volume":"21","author":"Aksoylar","year":"2020","journal-title":"Nat Immunol"},{"key":"10.1016\/j.ajo.2025.12.035_bib0012","doi-asserted-by":"crossref","first-page":"9999","DOI":"10.1073\/pnas.1822001116","article-title":"PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer","volume":"116","author":"Kamada","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ajo.2025.12.035_bib0013","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/nrneurol.2010.71","article-title":"systemic inflammatory cells fight off neurodegenerative disease","volume":"6","author":"Schwartz","year":"2010","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.ajo.2025.12.035_bib0014","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.clim.2010.03.001","article-title":"Human retinal pigment epithelium-induced CD4+CD25+ regulatory T cells suppress activation of intraocular effector T cells","volume":"136","author":"Horie","year":"2010","journal-title":"Clinical Immunology"},{"key":"10.1016\/j.ajo.2025.12.035_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13024-024-00724-w","article-title":"Regulatory T cells limit age-associated retinal inflammation and neurodegeneration","volume":"19","author":"Llori\u00e1n-Salvador","year":"2024","journal-title":"Mol Neurodegener"},{"key":"10.1016\/j.ajo.2025.12.035_bib0016","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1189\/jlb.3RI0615-239R","article-title":"Parainflammation, chronic inflammation, and age-related macular degeneration","volume":"98","author":"Chen","year":"2015","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.ajo.2025.12.035_bib0017","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.immuni.2023.01.004","article-title":"Principles of regulatory T cell function","volume":"56","author":"Dikiy","year":"2023","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.ajo.2025.12.035_bib0018","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1186\/s12943-024-02156-y","article-title":"Regulatory T cells in immune checkpoint blockade antitumor therapy","volume":"23","author":"Zhang","year":"2024","journal-title":"Mol Cancer"},{"key":"10.1016\/j.ajo.2025.12.035_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2021.108513","article-title":"New insights into oxidative stress and immune mechanisms involved in age-related macular degeneration tackled by novel therapies","volume":"188","author":"Potilinski","year":"2021","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ajo.2025.12.035_bib0020","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/978-3-030-66014-7_6","article-title":"Immunological aspects of age-related macular degeneration","volume":"1256","author":"Allingham","year":"2021","journal-title":"Adv Exp Med Biol"},{"issue":"9","key":"10.1016\/j.ajo.2025.12.035_bib0021","doi-asserted-by":"crossref","DOI":"10.1172\/JCI178296","article-title":"Complement regulation in the eye: implications for age-related macular degeneration","volume":"134","author":"Wilke","year":"2024","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ajo.2025.12.035_bib0022","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.3390\/cells12131708","article-title":"Beyond the complement cascade: insights into systemic immunosenescence and inflammaging in age-related macular degeneration and current barriers to treatment","volume":"12","author":"Khan","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.ajo.2025.12.035_bib0023","article-title":"Complement inhibitors for age-related macular degeneration","volume":"6","author":"Tzoumas","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ajo.2025.12.035_bib0024","doi-asserted-by":"crossref","first-page":"102350","DOI":"10.1016\/j.pneurobio.2022.102350","article-title":"Immune response in retinal degenerative diseases \u2013 time to rethink?","volume":"219","author":"Xu","year":"2022","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.ajo.2025.12.035_bib0025","article-title":"Contribution of interleukin-17A to retinal degenerative diseases","volume":"13","author":"Zhong","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.ajo.2025.12.035_bib0026","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1146\/annurev-immunol-042617-053245","article-title":"Complement and the regulation of T cell responses","volume":"36","author":"West","year":"2018","journal-title":"Annu Rev Immunol"},{"issue":"4","key":"10.1016\/j.ajo.2025.12.035_bib0027","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1167\/iovs.65.4.43","article-title":"CFH haploinsufficiency and complement alterations in early-onset macular degeneration","volume":"65","author":"Lim","year":"2024","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ajo.2025.12.035_bib0028","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with Immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ajo.2025.12.035_bib0029","doi-asserted-by":"crossref","first-page":"110154","DOI":"10.1016\/j.exer.2024.110154","article-title":"Blood integrin- and cytokine-producing T cells are associated with stage and genetic risk score in age-related macular degeneration","volume":"250","author":"Rijken","year":"2025","journal-title":"Exp Eye Res"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000293942500697X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000293942500697X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T08:19:48Z","timestamp":1781857188000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000293942500697X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":29,"alternative-id":["S000293942500697X"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2025.12.035","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reduced Risk of Non-Neovascular AMD in Cancer Patients Treated With Immune Checkpoint Inhibitors: A Propensity-Matched Cohort Study","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2025.12.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}